Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Drug-resistant TB news

Show

From To
Shortened regimen for MDR-TB shows good results for children

The use of the shortened 9-month treatment regimen for multidrug-resistant tuberculosis (MDR-TB), known as the ‘Bangladesh regimen’ has shown to be successful in 83% of children and adolescents

Published
18 July 2016
By
Lesley Odendal
Frequently asked questions about the implementation of the new WHO recommendation on the use of the shorter MDR-TB regimen

These FAQs address key points regarding the implementation of the WHO treatment guidelines for drug-resistant tuberculosis, 2016 update, in TB and TB/HIV programmes.

Published
15 June 2016
From
World Health Organization
The Worst Superbug? Tuberculosis

The ground-breaking publication of Lord Jim O'Neill's global Review on Antimicrobial Resistance (AMR) is the wake-up call the world desperately needs. Have no doubts: the 'superbugs' that develop antimicrobial resistance are a threat of immense proportions and have a potential impact of 10 million deaths a year by 2050 as antibiotic efficacy dwindles.

Published
20 May 2016
From
Huffington Post UK
Rapid diagnostic test and shorter, cheaper treatment signal new hope for multidrug-resistant tuberculosis patients

New WHO recommendations aim to speed up detection and improve treatment outcomes for multidrug resistant tuberculosis (MDR-TB) through use of a novel rapid diagnostic test and a shorter, cheaper treatment regimen.

Published
12 May 2016
From
World Health Organization
STREAM clinical study first to include bedaquiline to test shortened treatment regimens for multidrug-resistant III in Phase III trial

Stage 2 of the trial aims to reduce MDR-TB treatment from 24 months to 6 or 9 months.

Published
18 April 2016
From
International Union Against Tuberculosis and Lung Disease
Battling TB and other outbreaks “staff, stuff, space, and systems ” still lacking

Paul Farmer first saw multidrug-resistant tuberculosis in the early 1990s in Haiti, from where he smuggled a patient’s sputum sample to test for drug resistance in Boston. Months later, Partners in Health co-founder Dr. Jim Kim with other colleagues discovered a cluster of fifty MDR-TB patients in a squatter settlement of 100,000 in Lima, Peru. That’s when they started to talk to the world about the emergence of MDR-TB.

Published
24 March 2016
From
Science Speaks
Just 2% of people with the severest cases of drug-resistant TB currently have access to new, more effective treatments

Two years after two new drugs to treat tuberculosis—the first in over 50 years—were conditionally approved for use, only 2% of the 150,000 people who need them have been able to access them, according to Médecins Sans Frontières (MSF).

Published
24 March 2016
From
Médecins Sans Frontières
South Africa’s XDR-TB epidemic is due to transmission rather than evolution of resistant strains

A study in KwaZulu-Natal, South Africa, evaluating the social networks as well as clinical and genotypic data from individuals with extensively drug resistant tuberculosis (XDR-TB) has concluded that

Published
04 March 2016
By
Theo Smart
Empirical TB treatment comes up short again

A South African trial has found that a strategy allowing primary care nurses to quickly provide empirical tuberculosis (TB) treatment for newly diagnosed people with advanced HIV disease

Published
26 February 2016
By
Theo Smart
MDR-TB treatment: Six drugs better than five

A regimen containing six drugs was more likely to cure multi-drug resistant tuberculosis (MDR-TB) than a regimen containing five drugs, a nine-country observational study has

Published
13 January 2016
By
Keith Alcorn
← First12345...22Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close